Co-first authors: These authors contributed equally to this work.
In vitro cardiomyogenic differentiation of adipose-derived stromal cells using transforming growth factor-β1
Article first published online: 24 MAR 2009
Copyright © 2009 John Wiley & Sons, Ltd.
Cell Biochemistry and Function
Volume 27, Issue 3, pages 148–154, April 2009
How to Cite
Gwak, S.-J., Bhang, S. H., Yang, H. S., Kim, S.-S., Lee, D.-H., Lee, S.-H. and Kim, B.-S. (2009), In vitro cardiomyogenic differentiation of adipose-derived stromal cells using transforming growth factor-β1. Cell Biochem. Funct., 27: 148–154. doi: 10.1002/cbf.1547
- Issue published online: 27 MAR 2009
- Article first published online: 24 MAR 2009
- Manuscript Accepted: 23 JAN 2009
- Manuscript Revised: 18 JAN 2009
- Manuscript Received: 9 DEC 2008
- adult stem cell;
- adipose-derived stromal cells;
- cardiomyogenic differentiation;
- transforming growth factor-β1;
- osteogenic differentiation
Transplanting stem cells differentiated towards a cardiac lineage can regenerate cardiac muscle tissues to treat myocardial infarction. In this study, we tested the hypothesis that transforming growth factor-β1 (TGF-β1) induces cardiomyogenic differentiation of adipose- derived stromal cells (ADSCs) in vitro. Rat ADSCs were cultured with TGF-β1 (10 ng ml−1) for 2 weeks in vitro. ADSCs cultured without TGF-β1 served as a control. The mRNA expression of cardiac-specific gene was induced by TGF-β1, while the control culture did not show cardiac-specific gene expression. Immunocytochemical analyses showed that a small fraction of ADSCs cultured with TGF-β1 for 2 weeks stained positively for cardiac myosin heavy chain (MHC) and α-sarcomeric actin. Flow cytometric analyses showed that the proportion of cells expressing cardiac MHC increased with TGF-β1. However, no mesenchymal differentiation (e.g., osteogenic and adipogenic differentiation) was detected other than cardiomyogenic differentiation. These results showed that TGF-β1 induce ADSC cardiomyogenic differentiation in vitro, which could be useful for myocardial infarction stem cell therapy. Copyright © 2009 John Wiley & Sons, Ltd.